VKH
TCRT icon

Virtu KCG Holdings’s Alaunos Therapeutics TCRT Stock Holding History

Virtu KCG Holdings’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$151K Sell
162
-362
-69% -$355K ﹤0.01% 2290
2017
Q1 		$499K Sell
524
-648
-55% -$603K 0.01% 1372
2016
Q4 		$940K Buy
+1,172
New +$1.06M 0.02% 823
2016
Q3 		– Sell
-592
Closed -$487K – 3459
2016
Q2 		$487K Buy
+592
New +$645K 0.01% 1388
2016
Q1 		– Sell
-417
Closed -$520K – 3617
2015
Q4 		$520K Buy
417
+120
+40% +$198K 0.01% 1490
2015
Q3 		$402K Buy
+297
New +$490K 0.01% 1759
2015
Q2 		– Sell
-97
Closed -$157K – 3741
2015
Q1 		$157K Buy
+97
New +$144K ﹤0.01% 2503
2014
Q4 		– Sell
-253
Closed -$100K – 4222
2014
Q3 		$100K Buy
253
+97
+62% +$46.8K ﹤0.01% 3185
2014
Q2 		$94K Buy
156
+4
+3% +$2.23K ﹤0.01% 3308
2014
Q1 		$104K Buy
+152
New +$102K ﹤0.01% 3204
2013
Q4 		– Sell
-111
Closed -$66K – 4248
2013
Q3 		$66K Buy
+111
New +$50K ﹤0.01% 3464

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu KCG Holdings's TCRT Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Alaunos Therapeutics (TCRT) stake by 69% in Q2 2017, selling an estimated $355K and leaving 162 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Virtu KCG Holdings first reported a position in TCRT in Q3 2013 and has held it in 11 quarters since. The position peaked at $940K in Q4 2016. 122 funds tracked by Wall St. Rank hold TCRT as of Q2 2017.

  • Virtu KCG Holdings held 162 shares of Alaunos Therapeutics worth $151K as of Q2 2017.
  • Virtu KCG Holdings sold 362 Alaunos Therapeutics shares in Q2 2017, an estimated $355K.
  • Alaunos Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2290 holding.
  • Virtu KCG Holdings first reported a position in Alaunos Therapeutics in Q3 2013 and has held it in 11 quarters since.
  • Virtu KCG Holdings's Alaunos Therapeutics position peaked at $940K in Q4 2016.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.